Aptagen, LLC
BC 007 – Targeting Viral Proteins Essential for SARS-CoV-2 Replication (ID# 9134)
DNA
Receptor-binding domain (RBD) of the SARS-CoV-2 spike protein and RNA-dependent RNA polymerase (RdRp). As well as harmful autoantibodies that target G-protein-coupled receptors (GPCR-AABs).
Small Organic
55-87 µM (reported value)
Nuclear Magnetic Resonance Spectroscopy (NMR), High Sensitivity Isothermal Titration Calorimetry (ITC), Circular Dichroism Spectroscopy (CD)
Buffer: NaCl/sodium phosphate buffer
25°C
NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
β1-adrenergic receptor (β1-AAB) among GPCR-AABs, which are prevalent throughout dilated cardiomyopathy (DCM).
Aptamer BC 007, originally developed as a thrombin inhibitor, has been identified as an efficient binder to critical SARS-CoV-2 proteins, including the RBD of the spike protein and RdRp. This suggests potential for repurposing BC 007 as a therapeutic agent against COVID-19.
For kd affinity, the HRFYRLAN peptide sequence showed the highest affinity with Kd = 54.7 μM, followed by the peptide sequence YRLFRK with Kd = 86.7 μM
5'-dGpdGpdTpdTpdGpdGpdTpdGpdTpdGpdGpdTpdTpdGpdGp-3'
15
4726.1 g/mole
143300 (L)/(mole·cm)
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Weisshoff, H., Krylova, O., Nikolenko, H., Düngen, H. D., Dallmann, A., Becker, S., Göttel, P., Müller, J., & Haberland, A. (2020). Aptamer BC 007 - Efficient binder of spreading-crucial SARS-CoV-2 proteins. Heliyon, 6(11), e05421. https://doi.org/10.1016/j.heliyon.2020.e05421 Werner, S., Wallukat, G., Becker, N. P., Wenzel, K., Müller, J., Schimke, I., & Wess, G. (2020). The aptamer BC 007 for treatment of dilated cardiomyopathy: evaluation in Doberman Pinschers of efficacy and outcomes. ESC heart failure, 7(3), 844–855. https://doi.org/10.1002/ehf2.12628
Have your aptamer oligo synthesized ORDER
We are always looking for ways to improve. Please tell us what you think.